Dogwood Therapeutics Inc. has not released specific financial results in the provided document. However, a significant update involves a strategic transaction completed in Q4 2024, where Dogwood acquired Pharmagesic Holdings, including its novel pain development candidate, Halneuron®. As part of this transaction, CKLS, a publicly listed company on the Hong Kong exchange, received 211,383 shares of Common Stock and 2,108.3854 shares of Series A Preferred Stock, which is convertible into 10,000 shares of common stock each, pending shareholder approval. Additionally, a $20 million strategic financing loan from an affiliate of CK Life Sciences International was converted into 284.2638 shares of Series A-1 Preferred Stock in Q1 2025. Upon conversion of the Preferred Stock, CKLS and its affiliates will hold approximately 90% of Dogwood's common stock on a fully diluted basis. No specific guidance or outlook for sales, revenue, or profits has been disclosed in the document.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。